Royalty Pharma PLC - CL(RPRX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Royalty Pharma PLC - CL
RPRX.US
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
4.675 T
RPRX.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking48/189
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE12.17%B
    • Profit Margin33.86%A
    • Gross Margin131.32%A
  • Growth ScoreC
    • Revenue YoY7.80%C
    • Net Profit YoY-24.44%D
    • Total Assets YoY12.53%B
    • Net Assets YoY1.51%C
  • Cash ScoreB
    • Cash Flow Margin316.11%A
    • OCF YoY7.80%C
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreC
    • Gearing Ratio49.85%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX

    Market Beat·
    US
    RPRX
    +0.88%
    US
    IHE
    +0.34%
    Market Beat·
    US
    RPRX
    +0.88%
    US
    IHE
    +0.34%

    Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts

    Market Beat·
    US
    RPRX
    +0.88%
    US
    PBE
    0.00%
    US
    IXJ
    -0.08%
    Market Beat·
    US
    RPRX
    +0.88%
    US
    PBE
    0.00%
    US
    IXJ
    -0.08%

    The Company is in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg

    pressetext·
    US
    RPRX
    +0.88%
    US
    IHE
    +0.34%
    US
    SBIO
    +1.63%
    pressetext·
    US
    RPRX
    +0.88%
    US
    IHE
    +0.34%
    US
    SBIO
    +1.63%

    Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

    Tip Ranks·
    US
    RPRX
    +0.88%
    US
    VHT
    -0.20%
    US
    IHE
    +0.34%
    Tip Ranks·
    US
    RPRX
    +0.88%
    US
    VHT
    -0.20%
    US
    IHE
    +0.34%

    Royalty Pharma (RPRX) Gets a Buy from TD Cowen

    Tip Ranks·
    US
    RPRX
    +0.88%
    US
    BIB
    +2.80%
    US
    LABU
    +5.01%
    Tip Ranks·
    US
    RPRX
    +0.88%
    US
    BIB
    +2.80%
    US
    LABU
    +5.01%
    © 2026 Longbridge｜Disclaimer